Evidence map›Paper›PMID 40114026›Full record

ArticleNature metabolism2025

GLP-2 prevents antipsychotics-induced metabolic dysfunction in mice.

Yanmin Peng, Chenzhang Feng, Shiyu Peng, Ying Wang, Qian Zhang, Zhuolei Jiao, Huateng Cao, Shajin Huang, Peihuang Tian, Xiujia Sun and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yanmin Peng *Shanghai Key Laboratory of Psychotic Disorders, Brain Health Institute, National Center for Mental Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China. ameepeng@gmail.com.ORCID http://orcid.org/0000-0003-2038-3793
Chenzhang Feng *Institute of Neuroscience, State Key Laboratory of Neuroscience, Key Laboratory of Primate Neurobiology, Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Shanghai, China.
Shiyu PengShanghai Key Laboratory of Psychotic Disorders, Brain Health Institute, National Center for Mental Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ying WangInstitute of Neuroscience, State Key Laboratory of Neuroscience, Key Laboratory of Primate Neurobiology, Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Shanghai, China.
Qian ZhangInstitute of Neuroscience, State Key Laboratory of Neuroscience, Key Laboratory of Primate Neurobiology, Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Shanghai, China.
Zhuolei JiaoInstitute of Neuroscience, State Key Laboratory of Neuroscience, Key Laboratory of Primate Neurobiology, Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Shanghai, China.
Huateng CaoInstitute of Neuroscience, State Key Laboratory of Neuroscience, Key Laboratory of Primate Neurobiology, Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Shanghai, China.
Shajin HuangInstitute of Neuroscience, State Key Laboratory of Neuroscience, Key Laboratory of Primate Neurobiology, Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Shanghai, China.
Peihuang TianInstitute of Neuroscience, State Key Laboratory of Neuroscience, Key Laboratory of Primate Neurobiology, Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Shanghai, China.ORCID http://orcid.org/0009-0003-3686-7925
Xiujia SunShanghai Key Laboratory of Psychotic Disorders, Brain Health Institute, National Center for Mental Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xiaohong XuInstitutes of Brain Science, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0002-2447-3529
Yu FuInstitute of Molecular and Cell Biology, Agency for Science Technology and Research (A*STAR), Singapore, Singapore.ORCID http://orcid.org/0000-0002-9226-1982
Ji HuShanghai Key Laboratory of Psychotic Disorders, Brain Health Institute, National Center for Mental Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China. huji@shanghaitech.edu.cn.ORCID http://orcid.org/0000-0001-7930-2316
Zhe ZhangInstitute of Neuroscience, State Key Laboratory of Neuroscience, Key Laboratory of Primate Neurobiology, Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Shanghai, China. zhezhang@ion.ac.cn.ORCID http://orcid.org/0000-0002-0899-8077

Funding

China Postdoctoral Science Foundation 2020TQ0332, 2020M681415National Natural Science Foundation of China (National Science Foundation of China) 32071010，U23A20433National Natural Science Foundation of China (National Science Foundation of China) 32100799National Natural Science Foundation of China (National Science Foundation of China) 32330043, 32192414, 32192410National Natural Science Foundation of China (National Science Foundation of China) 82372583National Natural Science Foundation of China (National Science Foundation of China) 82430042Science and Technology Commission of Shanghai Municipality (Shanghai Municipal Science and Technology Commission) 22ZR1453900
6 · The paper itself

Abstract

Antipsychotic drugs have severe metabolic side effects. Acute use can induce hypothermia, while chronic use often leads to weight gain and associated disorders. However, no treatment is currently available for drug-induced hypothermia, and weight control measures lack evidence for long-term effectiveness. Here we demonstrate that a glucagon-like peptide 2 analogue, teduglutide, effectively prevents olanzapine-induced hypothermia and weight gain, and restores glucose tolerance and insulin sensitivity in mice. Mechanistically, olanzapine suppresses prodynorphin-expressing neurons in the ventromedial hypothalamus (VMH

Indexed as

Antipsychotic AgentsMetabolic DiseasesAnimalsHypothermiaMaleMiceMice, Inbred C57BLNeuronsOlanzapineWeight GainAntipsychotic AgentsOlanzapine

Identifiers

PMID40114026

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.